MYOM2 and Miyoshi myopathy: To address these limitations, we analyzed a large cohort of 2,270 patients with untreated SMM to identify new predictive features from evolving biomarkers (including M-protein, sFLC ratio, creatinine, and hemoglobin) and assess their contribution to longitudinal risk assessment of progression from SMM to MM.